Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $41,158,986.57 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 115,011 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $357.87, for a total value of $41,158,986.57. Following the completion of the transaction, the chief executive officer owned 125,799 shares of the company’s stock, valued at $45,019,688.13. This represents a 47.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Wednesday, August 12th, John Oyler sold 54,892 shares of BeOne Medicines stock. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80.
• On Tuesday, August 11th, John Oyler sold 70,907 shares of BeOne Medicines stock. The stock was sold at an average price of $361.90, for a total value of $25,661,243.30.
• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The stock was sold at an average price of $312.25, for a total value of $15,086,671.00.
• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.

BeOne Medicines Trading Down 2.4%

NASDAQ:ONC opened at $347.48 on Friday. The company has a market cap of $38.13 billion, a PE ratio of 61.18 and a beta of 0.49. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The company has a 50 day simple moving average of $304.47 and a two-hundred day simple moving average of $309.51. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $253.95 and a 12 month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The firm had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.66 billion. Research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 earnings per share for the current year.

Institutional Trading of BeOne Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets increased its stake in BeOne Medicines by 100.6% in the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after buying an additional 97,244 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of BeOne Medicines in the first quarter valued at about $19,438,000. SEB Asset Management AB bought a new position in shares of BeOne Medicines in the first quarter worth about $16,653,000. Capital International Sarl raised its stake in BeOne Medicines by 2.7% during the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after purchasing an additional 3,956 shares during the period. Finally, Rokos Capital Management LLP purchased a new position in BeOne Medicines in the 1st quarter worth approximately $4,256,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Morgan Stanley restated an “overweight” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Barclays raised their price objective on shares of BeOne Medicines from $403.00 to $407.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. upped their target price on shares of BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday, July 17th. Finally, Royal Bank Of Canada cut their price objective on shares of BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $402.14.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.